Immunoreactive peptides from Epstein-Barr virus
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 13, 2006
Issued Date -
N/A
app pub date -
Sep 15, 1993
filing date -
Sep 15, 1992
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Epstein-Barr virus (EBV) specific polypeptides consisting of a series of one to 1000 peptide units selected from the group consisting of peptide units .PHI., .GAMMA., .DELTA. and .OMEGA., wherein .PHI. is 25 amino acids or less and has the formula (.alpha.ETFTETWNRFITHTE.beta.) (SEQ ID NO:1), .GAMMA. is 25 amino acids or less and has the formula (.alpha.GMLEASEGLDGWIHQ.beta.) (SEQ ID NO:2), .DELTA. is 25 amino acids or less and has the formula (.alpha.HQQGGWSTLIEDNI.beta.) (SEQ ID NO:3), .OMEGA. is 25 amino acids or less and has the formula (.alpha.KQKHPKKVKQAFNPL.beta.) (SEQ ID NO:4), .alpha. and .beta. are each independently from 0 to 5 naturally occurring amino acids, and the polypeptide is capable of binding antibody in a specimen from an individual with Epstein-Barr virus (EBV)-associated disease are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully